Cardiometabolic diseases

Cardiometabolic diseases present a major healthcare burden^1‑3 and cardiovascular diseases are a significant cause of premature death;^1‑4 18.5 million deaths per year, one-third of all deaths globally.⁵

Cardiometabolic conditions form a continuum that starts from cardiovascular risk factors, and without intervention, can progress to myocardial infarction, stroke, heart failure and death.^21‑23 Due to this high interdependence, they can no longer be treated in isolation. Fragmented care can lead to redundant diagnostic testing and higher healthcare costs.^22,29‑31

Diagnostic tests play a crucial part in healthcare. They account for only a fraction of the total healthcare spending (<2%), while informing ~70% of clinical decisions.⁶

As the global market leader in in vitro diagnostics, Roche continuously invests in evidence generation on new uses of biomarkers to improve cardiometabolic care and outcomes for patients.^10‑12 In 2023 alone, we invested CHF 13.2 million in research and development and delivered 6 new platforms, 21 diagnostic tests and 7 digital solutions,¹³ alongside CMD pipeline acceleration through partnerships and acquisitions.¹⁴

With biomarkers and digital solutions, Roche enables earlier diagnosis, reducing time to discharge, and providing information for personalised treatment plans.^16,32

At Roche we develop and offer innovative decision support and disease management solutions to optimise patient management across the cardiac continuum of care.

Addressing unmet needs in cardiometabolic disease (CMD) has direct operational and clinical benefits, as CMDs can lead to unnecessary hospital admissions, overcrowded emergency departments, high bed occupancy and a negative impact on quality of care, with 44%–96% of heart failure care cost attributed to hospitalisations globally.^24‑28

Cardiometabolic conditions are highly interdependent and can no longer be treated in isolation. They need coordinated care from multidisciplinary teams as fragmented care leads to redundant diagnostic testing and higher costs.^22,29-31

Roche empowers healthcare professionals with earlier diagnosis, reducing time to discharge, and providing information for personalised treatment plans by offering biomarkers and solutions used across the continuum of cardiac care.^16,23

• Our validated cobas® h 232 and Elecsys® offering is standardised across the laboratory and at the point of care, providing comparable and reliable results for consistent management wherever a patient receives care.^8,33,34
• Our connected diagnostic solutions and the ability to compare results across diagnostic platforms^8,33 can help diagnose patients earlier, which is invaluable in preventing disease progression, provides clinical improvements and can influence treatment decisions across the continuum of care.^32,35,36
• The Roche Healthcare Consulting team can work with healthcare organisations to understand their needs, ensuring that solutions are successfully localised, scaled and integrated in a way that brings maximum benefits to patients and healthcare professionals.³⁷
• Our Advanced Access DMS platform seamlessly integrates existing stand-alone components like remote patient monitoring and diagnostic insights with HCP’s clinical acumen.
• With navify® Algorithm Suite, healthcare professionals can easily order the medical algorithms they need from Roche, generating actionable insights to drive personalised healthcare and improve patient care.³⁹

We invest in evidence creation to gain new insights that will transform diagnostics and drive further development of cardiometabolic disease (CMD) guidelines and policies, ultimately supporting improved outcomes for patients.^10‑12

• Through our continued investment into research and development, we have gathered the evidence needed to broaden the range of intended uses of our biomarkers, as with NT-proBNP and cTnT-hs.^8,9
• Our troponin and NT-proBNP assays have been featured in over 3,600[DoF] publications, with breakthrough publications over nearly two decades that have helped the scientific community make informed decisions.^{10-12,40‑47}
• We have invested in, co-sponsored or supported valuable evidence generation to aid experts in developing guidelines, leading to better protocols and new policies.^{10,11,48‑50}
• Roche is committed to creating evidence to support the clinical implementation of best practices in cardiometabolic diseases; for example, the impact of STRONG-HF goes beyond the clinical trial and will influence real-world patient care and management.